The interactions of obesity, inflammation and insulin resistance in breast cancer

Cancers

Volumn 7, Issue 4, 2015, Pages 2134-2168

  Rose, David P ^a   Gracheck, Peter J ^a   Davis, Linda Vona ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

Breast cancer; Inflammation; Insulin

Indexed keywords

AROMATASE; CYCLOOXYGENASE 2; ESTROGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; ANGIOGENESIS; BODY MASS; BREAST CANCER; BREAST CARCINOGENESIS; CANCER RISK; CELL GROWTH; CELL INVASION; CELL PROLIFERATION; DISEASE ASSOCIATION; ENZYME ACTIVITY; ESTROGEN SYNTHESIS; HUMAN; HYPERINSULINEMIA; INFLAMMATION; INSULIN RESISTANCE; MACROPHAGE; METASTASIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; POSTMENOPAUSE; PROTEIN EXPRESSION; REVIEW; TUMOR CELL;

EID: 84945376575     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers7040883     Document Type: Review

References (133)

1. American Cancer Society. Cancer Facts and Figures; American Cancer Society: Atlanta, GA, USA, 2014.
2. Ferlay, J.; Steliarova-Foucher, E.; Lortet-Tieulent, J.; Rosso, S.; Coebergh, J.W.W.; Comber, H.; Forman, D.; Bray, F. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur. J. Cancer 2013, 49, 1374-1403. [CrossRef] [PubMed]
3. De Waard, F.; Baanders-van Halewijin, E.A.; Huizinga, J. The bimodal age distribution of patients with mammary carcinoma. Evidence for the existence of 2 types of human breast cancer. Cancer 1964, 17, 141-151. [PubMed]
4. De Waard, F.; Baanders-van Halewijn, E.A. A prospective study in general practice on breast-cancer risk in postmenopausal women. Int. J. Cancer. 1974, 14, 153-160. [CrossRef] [PubMed]
5. Ogden, C.L. Prevalence of obesity and trends in body mass index among US children and adolescents, 1999-2010. J. Am. Med. Assoc. 2012, 307, 483-490. [CrossRef] [PubMed]
6. Cowie, C.C.; Rust, K.F.; Ford, E.S.; Eberhardt, M.S.; Byrd-Holt, D.D.; Li, C.; Williams, D.E.; Gregg, E.W.; Bainbridge, K.E.; Saydah, S.H.; et al. Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006. Diabetes Care. 2009, 32, 287-294. [CrossRef] [PubMed]
7. Coldlitz, G.A.; Willet, W.C.; Stampfer, M.J.; Manson, J.E.; Hennekens, C.H.; Arky, R.A.; Speizer, F.E. Weight as a risk factor for clinical diabetes in women. Am. J. Epidemiol. 1990, 132, 501-513.
8. Cali, A.M.; Caprio, S. Prediabetes and type 2 diabetes in youth: An emerging epidemic disease? Curr. Opin. Endocrinol. Diabetes Obes. 2008, 15, 123-127. [CrossRef] [PubMed]
9. Shoelson, S.E.; Lee, J.; Goldfine, A.B. Review series Inflammation and insulin resistance. J. Clin. Investig. 2006, 116, 1793-1801. [CrossRef] [PubMed]
10. Onat, A.; Avci, G.S.; Barlan, M.M.; Uyarel, H.; Uzunlar, B.; Sansoy, V. Measures of abdominal obesity assessed for visceral adiposity and relation to coronary risk. Int. J. Obes. Relat. Metab. Disord. 2004, 28, 1018-1025. [CrossRef] [PubMed]
11. Gauthier, M.S.; Ruderman, M.B. Adipose tissue inflammation and insulin resistance: All obese humans are not created equal. Biochem. J. 2010, 430, E1-E4. [CrossRef] [PubMed]
12. Goran, M.I.; Alderete, T.L. Targeting adipose tissue inflammation to treat the underlying basis of the metabolic complications of obesity. Nestle Nutr. Inst. Workshop Ser. 2012, 73, 49-60. [PubMed]
13. Weisberg, S.P.; McCann, D.; Desai, M.; Rosenbaum, M.; Leibel, R.L.; Ferrante, A.W. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Investig. 2003, 112, 1796-1808. [CrossRef] [PubMed]
14. Strissel, K.J.; Stancheva, Z.; Miyoshi, H.; Perfield, J.W.; DeFuria, J.; Jick, Z.; Greenberg, A.S.; Obin, M.S. Adipocyte death, adipose tissue remodeling, and obesity complications. Diabetes 2007, 56, 2910-2918. [CrossRef] [PubMed]
15. Barbarroja, N.; Lopez-Pedera, R.; Mayas, M.D.; Garcia-Fuentes, E.; Garrido-Sanchez, L.; Macias-Gonzalez, M.; El Bekay, R.; Vidal-Puig, A.; Tinahones, F.J. The obese healthy paradox: Is inflammation the answer? Biochem. J. 2010, 430, 141-149. [CrossRef] [PubMed]
16. Barbarroja, N.; Lopez-Pedrera, C.; Garrido-Sanchez, L.; Mayas, M.D.; Oliva-Olivera, W.; Bernal-Lopez, M.R.; El Bekay, R.; Tinahones, F.J. Progression from high insulin resistance to type 2 diabetes does not entail additional visceral adipose tissue inflammation. PLOS ONE 2012, 7. [CrossRef]
17. Chen, A.; Mumick, S.; Zhang, C.; Lamb, J.; Dai, H.; Weingarth, D.; Mudgett, J.; Chen, H.; MacNeil, D.J.; Reitman, M.L.; et al. Diet induction of monocyte chemoattractant protein-1 and its impact on obesity. Obes. Res. 2005, 13, 1311-1320. [CrossRef] [PubMed]
18. Cinti, S.; Mitchell, G.; Barbatelli, G.; Murano, I.; Ceresi, E.; Faloia, E.; Wang, S.; Fortier, M.; Greenberg, A.S.; Obin, M.S. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J. Lipid Res. 2005, 46, 2347-2355. [CrossRef] [PubMed]
19. Carey, A.L.; Bruce, C.R.; Sacchetti, M.; Anderson, M.J.; Olsen, D.B.; Saltin, B.; Hawley, J.A.; Febbraio, M. Interleukin-6 and tumor necrosis factor-alpha are not increased in patients with Type 2 diabetes: Evidence that plasma interleukin-6 is related to fat mass and not insulin responsiveness. Diabetologia 2004, 47, 1029-1037. [CrossRef] [PubMed]
20. Bal, Y.; Adas, M.; Helvaci, A. Evaluation of the relationship between insulin resistance and plasma tumor necrosis factor-alpha, interleukin-6 and C-reactive protein levels in obese women. Bratisl. Lek. Listy 2010, 111, 200-204. [PubMed]
21. Lê, K.A.; Mahurkar, S.; Alderete, T.L.; Hasson, R.E.; Adam, T.C.; Kim, J.S.; Beale, E.; Xie, C.; Greenberg, A.S.; Allayee, H.; et al. Subcutaneous adipose tissue macrophage infiltration is associated with hepatic and visceral fat deposition, hyperinsulinemia, and stimulation of NF-kB stress pathway. Diabetes 2011, 60, 2802-2809.
22. Bremer, A.A.; Devaraj, J.; Afify, A.; Jilal, I. Adipose tissue dysregulation in patients with metabolic syndrome. J. Clin. Endocrinol. Meab. 2011, 96, E1782-E1788. [CrossRef] [PubMed]
23. Kim, O.Y.; Chae, J.S.; Paik, J.K.; Seo, H.S.; Jang, Y.; Cavailon, J.M.; Lee, J.H. Effects of aging and menopause on serum interleukin-6 levels and peripheral blood mononuclear cell cytokine production in healthy nonobese women. Age 2012, 2, 415-425. [CrossRef] [PubMed]
24. Lumeng, C.N.; Bodzin, J.L.; Saltiel, A.R. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J. Clin. Investig. 2007, 117, 175-184. [CrossRef] [PubMed]
25. Gordon, S. Alternative activation of macrophages. Nat. Rev. Immunol. 2003, 3, 23-35. [CrossRef] [PubMed]
26. Murdoch, C.; Muthana, M.; Coffelt, S.B.; Lewis, C.E. The role of myeloid cells in the promotion of tumour angiogenesis. Nat. Rev. Cancer 2008, 8, 618-631. [CrossRef] [PubMed]
27. Keeley, E.C.; Mehrad, B.; Strieter, R.M. Chemokines as mediators of tumor angiogenesis and neovascularization. Exp. Cell Res. 2011, 317, 685-690. [CrossRef] [PubMed]
28. Liu, M.J.; Bao, S.; Bolin, E.R.; Burris, D.L.; Xu, X.; Sun, Q.; Killilea, D.W.; Shen, Q.; Ziouzenkova, O.; Belury, M.; et al. Zinc deficiency augments leptin production and exacerbates macrophage infiltration into adipose tissue in mice fed a high-fat diet. J. Nutr. 2013, 143, 1036-1045. [CrossRef] [PubMed]
29. Heilbronn, L.K.; Campbell, L.V. Adipose tissue macrophages, low grade inflammation and insulin resistance in human obesity. Curr. Pharm. Des. 2008, 14, 1225-1230. [CrossRef] [PubMed]
30. Fujii, M.; Inoguchi, T.; Batchuluun, B.; Sugiyama, N.; Kobayashi, K.; Sonoda, N.; Takayanagi, R. CTLA-4Ig immunotherapy of obesity-induced insulin resistance by manipulation of macrophage polarization in adipose tissues. Biochem. Biophys. Res. Commun. 2013, 438, 103-109. [CrossRef] [PubMed]
31. Hansen, D.; Dendale, P.; Beelen, M.; Jonkers, R.M.; Mullens, A.; Corluy, L.; Meeusen, R.; van Loon, L.J.C. Plasma adipokine and inflammatory marker concentrations are altered in obese, as opposed to non-obese, type 2 diabetes patients. Eur. J. Appl. Physiol. 2010, 109, 397-404. [CrossRef] [PubMed]
32. Pradhan, D.; Manson, J.E.; Rifai, N.; Buring, J.E.; Ridker, P.M. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001, 286, 327-334. [CrossRef] [PubMed]
33. Bastard, J.P.; Maachi, M.; Lagathu, C.; Kim, M.J.; Caron, M.; Vidal, H.; Capeau, J.; Feve, B. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur. Cytokine Netw. 2006, 17, 4-12. [PubMed]
34. Engeli, S.; Feldpausch, M.; Gorzelniak, K.; Hartwig, F.; Heintze, U.; Janke, J.; Möhlig, M.; Pfeiffer, A.F.; Luft, F.C.; Sharma, A.M. Association between adiponectin and mediators of inflammation in obese women. Diabetes 2003, 52, 942-947. [CrossRef] [PubMed]
35. Ohashi, K.; Parker, J.L.; Ouchi, N.; Higuchi, A.; Vita, J.A.; Gocke, N.; Pedersen, A.A.; Kalthoff, C.; Tullin, S.; Summer, R.; et al. Adiponectin promotes macrophage polarization toward an anti-inflammatory phenotype. J. Biol. Chem. 2010, 285, 6153-6160. [CrossRef] [PubMed]
36. Flachs, P.; Mohamed-Ali, V.; Horakova, O.; Rossmeisl, M.; Hosseinzadeh-Attar, M.J.; Hensler, M.; Ruzickova, J.; Kopecky, J. Polyunsaturated fatty acids of marine origin induce adiponectin in mice fed a high-fat diet. Diabetologia 2006, 49, 394-397. [CrossRef] [PubMed]
37. Micallef, M.; Munro, I.; Phang, M.; Garg, M. Plasma n-3 Polyunsaturated Fatty Acids are negatively associated with obesity. Br. J. Nutr. 2009, 102, 1370-1374. [CrossRef] [PubMed]
38. Nomura, S.; Shouzu, A.; Omoto, S.; Inami, N.; Ueba, T.; Urase, F.; Maeda, Y. Effects of eicosapentaenoic acid on endothelial cell-derived microparticles, angiopoietins and adiponectin in patients with type 2 diabetes. J. Atheroscler. Thromb. 2009, 16, 83-90. [CrossRef] [PubMed]
39. Vona-Davis, L.; Rose, D.P. Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocr. Relat. Cancer 2007, 14, 189-206. [CrossRef] [PubMed]
40. Vona-Davis, L.; Rose, D.P. Type 2 diabetes and obesity metabolic interactions: Common factors for breast cancer risk and novel approaches to prevention and therapy. Curr. Diabetes Rev. 2012, 8, 116-130. [CrossRef] [PubMed]
41. Klöting, N.; Fasshauer, M.; Dietrich, A.; Kovacs, P.; Schön, M.R.; Kern, M.; Stumvoll, M.; Blüher, M. Insulin-sensitive obesity. Am. J. Physiol. Endocrinol. Metab. 2010, 299, E506-E515.
42. Ndumele, C.E.; Nasir, K.; Conceiçao, R.D.; Carvalho, J.A.M.; Blumenthal, R.S.; Santos, R.D. Hepatic steatosis, obesity, and the metabolic syndrome are independently and additively associated with increased systemic inflammation. Arterioscler. Thromb. Vasc. Biol. 2011, 31, 1927-1932. [CrossRef] [PubMed]
43. Itoh, M.; Kato, H.; Suganami, T.; Konuma, K.; Marumoto, Y.; Terai, S.; Sakugawa, H.; Kanai, S.; Hamaguchi, M.; Fukaishi, T.; et al. Hepatic crown-like structure: A unique histological feature in non-alcoholic steatohepatitis in mice and humans. PLOS ONE 2013, 8. [CrossRef] [PubMed]
44. Kanda, H.; Tateya, S.; Tamori, Y.; Kotani, K.; Hiasa, K.; Kitazawa, R.; Kitazawa, S.; Miyachi, H.; Maeda, S.; Egashira, K.; et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J. Clin. Investig. 2006, 116, 1494-1505. [CrossRef] [PubMed]
45. Birkenfeld, A.L.; Shulman, G.I. Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 Diabetes. Hepatology 2014, 59, 713-723. [CrossRef] [PubMed]
46. Stefan, N.; Kantartzis, K.; Machann, J.; Schick, F.; Thamer, C.; Rittig, K.; Balletshofer, B.; Machicao, F.; Fritsche, A.; Häring, H.U. Identification and characterization of metabolically benign obesity in humans. Arch. Intern. Med. 2008, 168, 1609-1616. [CrossRef] [PubMed]
47. Wildman, R.P.; Muntner, P.; Reynolds, K.; Mcginn, A.P. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering. Arch. Intern. Med. 2008, 168, 1617-1624. [CrossRef] [PubMed]
48. Phillips, C.M.; Perry, I.J. Does inflammation determine metabolic health status in obese and nonobese adults? J. Clin. Endocrinol. Metab. 2013, 98, 1610-1619. [CrossRef] [PubMed]
49. Conus, F.; Rabasa-Lhoret, R.; Peronnet, F. Characteristics of metabolically obese normal-weight (MONW) subjects. Appl. Physiol. Nutr. Metab. 2007, 32, 4-12. [CrossRef] [PubMed]
50. Wildman, R.P.; Kaplan, R.; Manson, J.E.; Rajkovic, A.; Connelly, S.A.; Mackey, R.H.; Tinker, L.F.; Curb, J.D.; Eaton, C.B.; Wassertheil-Smoller, S. Body size phenotypes and inflammation in the Women’s Health Initiative Observational Study. Obesity 2011, 19, 1482-1491. [CrossRef] [PubMed]
51. Rose, D.P.; Vona-Davis, L. Biochemical and molecular mechanisms for the association between obesity, chronic inflammation, and breast cancer. Biofactors 2013, 40, 12. [CrossRef] [PubMed]
52. Pierobon, M.; Frankenfeld, C.L. Obesity as a risk factor for triple-negative breast cancers: A systematic review and meta-analysis. Breast Cancer Res. Treat. 2013, 137, 307-314. [CrossRef] [PubMed]
53. Huang, Z.; Willett, W.C.; Colditz, G.A.; Hunter, D.J.; Manson, J.E.; Rosner, B.; Speizer, F.E.; Hankinson, S.E. Waist circumference, waist:hip ratio, and risk of breast cancer in the Nurses’ Health Study. Am. J. Epidemiol. 1999, 150, 1316-1324. [CrossRef] [PubMed]
54. Connolly, B.S.; Barnett, C.; Vogt, K.N.; Li, T.; Stone, J.; Boyd, N.F. A meta-analysis of published literature on waist-to-hip ratio and risk of breast cancer. Nutr. Cancer 2002, 44, 127-138. [CrossRef] [PubMed]
55. Protani, M.; Coory, M.; Martin, J.H. Effect of obesity on survival of women with breast cancer: Systematic review and meta-Analysis. Breast Cancer Res. Treat. 2010, 123, 627-635. [CrossRef] [PubMed]
56. Niraula, S.; Ocana, A.; Ennis, M.; Goodwin, P.J. Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: A meta-analysis. Breast Cancer Res. Treat. 2012, 134, 769-781. [CrossRef] [PubMed]
57. Sestak, I.; Distler, W.; Forbes, J.F.; Dowsett, M.; Howell, A.; Cuzick, J. Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: An exploratory analysis from the ATAC trial. J. Clin. Oncol. 2010, 28, 3411-3415. [CrossRef] [PubMed]
58. Pfeiler, G.; Stöger, H.; Dubsky, P.; Mlineritsch, B.; Singer, C.; Balic, M.; Fitzal, F.; Moik, M.; Kwasny, W.; Selim, U.; et al. Efficacy of tamoxifen ± aminoglutethimide in normal weight and overweight postmenopausal patients with hormone receptor-positive breast cancer: An analysis of 1509 patients of the ABCSG-06 trial. Br. J. Cancer 2013, 108, 1408-1414. [CrossRef] [PubMed]
59. Autier, P.; Koechlin, A.; Boniol, M.; Mullie, P.; Bolli, G.; Rosenstock, J.; Boyle, P. Serum insulin and C-peptide concentration and breast cancer: A meta-analysis. Cancer Causes Control. 2013, 24, 873-883. [CrossRef] [PubMed]
60. Kaaks, R.; Lundin, E.; Manjer, J.; Rinaldi, S.; Biessy, C.; Söderberg, S.; Lenner, P.; Janzon, L.; Riboli, E.; Berglund, G.; et al. Prospective study of IGF-I, IGF-binding proteins, and breast cancer risk, in northern and southern Sweden. Cancer Causes Control 2002, 13, 307-316. [CrossRef] [PubMed]
61. Mink, P.J.; Shahar, E.; Rosamond, W.D.; Alberg, A.J.; Folsom, A.R. Serum insulin and glucose levels and breast cancer incidence: The atherosclerosis risk in communities study. Am. J. Epidemiol. 2002, 156, 349-352. [CrossRef] [PubMed]
62. Gunter, M.J.; Hoover, D.R.; Yu, H.; Wassertheil-Smoller, S.; Rohan, T.E.; Manson, J.E.; Li, J.; Ho, G.Y.; Xue, X.; Andersen, G.L.; et al. Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J. Natl. Cancer Inst. 2009, 101, 48-60. [CrossRef] [PubMed]
63. Kabat, G.C.; Kim, M.; Caan, B.J.; Chlebowski, R.T.; Gunter, M.J.; Ho, G.Y.F.; Rodriguez, B.L.; Shikany, J.M.; Strickler, H.D.; Vitolins, M.Z.; et al. Repeated measures of serum glucose and insulin in relation to postmenopausal breast cancer. Int. J. Cancer 2009, 125, 2704-2710. [CrossRef] [PubMed]
64. Ikeda, Y.; Suehiro, T.; Nakamura, T.; Kumon, Y.; Hashimoto, K. Clinical significance of the insulin resistance index as assessed by homeostasis model assessment. Endocr. J. 2001, 48, 81-86. [CrossRef] [PubMed]
65. Goodwin, P.J.; Ennis, M.; Pritchard, K.I.; Trudeau, M.E.; Koo, J.; Madarnas, Y.; Hartwick, W.; Hoffman, B.; Hood, N. Fasting insulin and outcome in early-stage breast cancer: Results of a prospective cohort study. J. Clin. Oncol. 2002, 20, 42-51. [CrossRef] [PubMed]
66. Goodwin, P.J.; Ennis, M.; Pritchard, K.I.; Trudeau, M.E.; Koo, J.; Taylor, S.K.; Hood, N. Insulin-and obesity-related variables in early-stage breast cancer: Correlations and time course of prognostic associations. J. Clin. Oncol. 2012, 30, 164-171. [CrossRef] [PubMed]
67. Borugian, M.J.; Sheps, S.B.; Kim-Sing, C.; van Patten, C.; Potter, J.D.; Dunn, B.; Gallagher, R.P.; Hislop, T.G. Insulin, macronutrient intake, and physical activity: Are potential indicators of insulin resistance associated with mortality from breast cancer? Cancer Epidemiol. Biomarkers Prev. 2004, 13, 1163-1172. [PubMed]
68. Rose, D.P.; Vona-Davis, L. Influence of obesity on breast cancer receptor status and prognosis. Expert Rev. Anticancer Ther. 2009, 9, 1091-1101. [CrossRef] [PubMed]
69. Larsson, S.C.; Mantzoros, C.S.; Wolk, A. Diabetes mellitus and risk of breast cancer: A meta-analysis. Int. J. Cancer 2007, 121, 856-862. [CrossRef] [PubMed]
70. Boyle, P.; Boniol, M.; Koechlin, A.; Robertson, C.; Valentini, F.; Coppens, K.; Fairley, L.L.; Boniol, M.; Zheng, T.; Zhang, Y.; et al. Diabetes and breast cancer risk: A meta-analysis. Br. J. Cancer 2012, 107, 1608-1617. [CrossRef] [PubMed]
71. De Bruijn, K.M.J.; Arends, L.R.; Hansen, B.E.; Leeflang, S.; Ruiter, R.; van Eijck, C.H.J. Systematic review and meta-analysis of the association between diabetes mellitus and incidence and mortality in breast and colorectal cancer. Br. J. Surg. 2013, 100, 1421-1429. [CrossRef] [PubMed]
72. Peairs, K.S.; Barone, B.B.; Snyder, C.F.; Yeh, H.C.; Stein, K.B.; Derr, R.L.; Brancati, F.L.; Wolff, A.C. Diabetes mellitus and breast cancer outcomes: A systematic review and meta-analysis. J. Clin. Oncol. 2011, 29, 40-46. [CrossRef] [PubMed]
73. Fleming, S.T.; Rastogi, A.; Dmitrienko, A.; Johnson, K.D. A comprehensive prognostic index to predict survival based on multiple comorbidities: A focus on breast cancer. Med. Care 1999, 37, 601-614. [CrossRef] [PubMed]
74. Srokowski, T.P.; Fang, S.; Hortobagyi, G.N.; Giordano, S.H. Impact of diabetes mellitus on complications and outcomes of adjuvant chemotherapy in older patients with breast cancer. J. Clin. Oncol. 2009, 27, 2170-2176. [CrossRef] [PubMed]
75. Schrauder, M.G.; Fasching, P.A.; Häberle, L.; Lux, M.P.; Rauh, C.; Hein, A.; Bayer, C.M.; Heusinger, K.; Hartmann, A.; Strehl, J.D.; et al. Diabetes and prognosis in a breast cancer cohort. J. Cancer Res. Clin. Oncol. 2011, 137, 975-983. [CrossRef] [PubMed]
76. Jiralerspong, S.; Kim, E.S.; Dong, W.; Feng, L.; Hortobagyi, G.N.; Giordano, S.H. Obesity, diabetes, andsurvival outcomes in a large cohort of early-stage breast cancer patients. Ann. Oncol. 2013, 24, 2506-5214. [CrossRef] [PubMed]
77. Druesne-Pecollo, N.; Touvier, M.; Barrandon, E.; Chan, D.S.; Norat, T.; Zelek, L.; Hercberg, S.; Latino-Martel, P. Excess body weight and second primary cancer risk after breast cancer: A systematic review and meta-analysis of prospective studies. Breast Cancer Res. Treat. 2012, 135, 647-654. [CrossRef] [PubMed]
78. Li, C.L.; Daling, J.R.; Tang, M.T.; Malone, K.E. Relationship between diabetes and risk of second primary contralateral breast cancer. Breast Cancer Res. Treat. 2011, 125, 545-551. [CrossRef] [PubMed]
79. Wolf, I.; Sadetzki, S.; Gluck, I.; Oberman, B.; Ben-David, M.; Papa, M.Z.; Catane, R.; Kaufman, B. Association between diabetes mellitus and adverse characteristics of breast cancer at presentation. Eur. J. Cancer 2006, 42, 1077-1082. [CrossRef] [PubMed]
80. Liao, S.; Li, J.; Wang, L.; Zhang, Y.; Wang, C.; Hu, M.; Ma, B.; Wang, G.; Sun, S. Type 2 diabetes mellitus and characteristics of breast cancer in China. Asian Pac. J. Cancer Prev. 2010, 11, 933-937. [PubMed]
81. Li, Z.; Luo, Y.; Gong, Y.; Liu, Y.; Qiu, W.; Tu, J. Clinical features and molecular phenotypes of breast cancer in patients with type-2 diabetes mellitus. Asian Pac. J. Cancer Prev. 2011, 12, 2183-2188. [PubMed]
82. Hou, G.; Zhang, S.; Zhang, X.; Wang, P.; Hao, X.; Zhang, J. Clinical pathological characteristics and prognostic analysis of 1,013 breast cancer patients with diabetes. Breast Cancer Res. Treat. 2013, 137, 807-816. [CrossRef] [PubMed]
83. De Azambuja, E.; Cardoso, F.; de Castro, G.; Colozza, M.; Mano, M.S.; Durbecq, V.; Sotiriou, C.; Larsimont, D.; Piccart-Gebhart, M.J.; Paesmans, M. Ki-67 as prognostic marker in early breast cancer: A meta-analysis of published studies involving 12,155 patients. Br. J. Cancer 2007, 96, 1504-1513. [CrossRef] [PubMed]
84. Kameni, A.; Anderson, M.L.; White, E.; Taplin, S.H.; Porter, P.; Ballard-Barbash, R.; Malone, K.; Buist, D.S. Body mass index, tumor characteristics, and prognosis following diagnosis of early-stage breast cancer in a mammographically screened population. Cancer Causes Control 2013, 24, 305-312. [CrossRef] [PubMed]
85. Hadad, S.; Iwamoto, T.; Jordan, L.; Purdie, C.; Bray, S.; Baker, L.; Jellema, G.; Deharo, S.; Hardie, D.G.; Moulder-Thompson, S.; et al. Evidence for biological effects of metformin in operable breast cancer: A pre-operative, window-of-opportunity, randomized trial. Breast Cancer Res. Treat. 2011, 128, 783-794. [CrossRef] [PubMed]
86. Michels, K.B.; Solomon, C.G.; Hu, F.B.; Rosner, B.A.; Hankinson, S.E.; Colditz, G.A.; Manson, J.E. Type 2 diabetes and subsequent incidence of breast cancer in the nurses’ health study. Diabetes Care 2003, 26, 1752-1758. [CrossRef] [PubMed]
87. Amadou, A.; Ferrari, P.; Muwonge, R.; Moskal, A.; Biessy, C.; Romieu, I.; Hainaut, P. Overweight, obesity and risk of premenopausal breast cancer according to ethnicity: A systematic review and dose-response meta-analysis. Obes. Rev. 2013, 14, 665-678. [CrossRef] [PubMed]
88. Wu, A.H.; Yu, M.C.; Tseng, C.C.; Stanczyk, F.Z.; Pike, M.C. Diabetes and risk of breast cancer in Asian-American women. Carcinogenesis 2007, 28, 1561-1566. [CrossRef] [PubMed]
89. Razak, F.; Anand, S.S.; Shannon, H.; Vuksan, V.; Davis, B.; Jacobs, R.; Teo, K.K.; McQueen, M.; Yusuf, S. Defining obesity cut points in a multiethnic population. Circulation 2007, 115, 2111-2118. [CrossRef] [PubMed]
90. Key, T.; Appleby, P.; Barnes, I.; Reeves, G. Endogenous Sex Hormones and Breast Cancer in Postmenopausal Women: Reanalysis of nine prospective studies. J. Natl. Cancer Inst. 2002, 94, 606-616.[PubMed]
91. Rinaldi, S.; Key, T.J.; Peeters, P.H.M.; Lahmann, P.H.; Lukanova, A.; Dossus, L.; Biessy, C.; Vineis, P.; Sacerdote, C.; Berrino, F.; et al. Anthropometric measures, endogenous sex steroids and breast cancer risk in postmenopausal women: A study within the EPIC cohort. Int. J. Cancer 2006, 118, 2832-2839. [CrossRef] [PubMed]
92. Rose, D.P.; Vona-Davis, L. Interaction between menopausal status and obesity in affecting breast cancer risk. Maturitas 2010, 66, 33-38. [CrossRef] [PubMed]
93. Tekmal, R.R.; Kirma, N.; Gill, K.; Fowler, K. Aromatase overexpression and breast hyperplasia, an in vivo model-continued overexpression of aromatase is sufficient to maintain hyperplasia without circulating estrogens, and aromatase inhibitors abrogate these preneoplastic changes in mammary glands. Endocr. Relat. Cancer 1999, 6, 307-314. [CrossRef] [PubMed]
94. McTernan, P.G.; Anwar, A.; Eggo, M.C.; Barnett, A.H.; Stewart, P.M.; Kumar, S. Gender differences in the regulation of P450 aromatase expression and activity in human adipose tissue. Int. J. Obes. Relat. Metab. Disord. 2000, 24, 875-881. [PubMed]
95. Ding, E.L.; Song, Y.; Manson, J.E.; Rifai, N.; Buring, J.E.; Liu, S. Plasma sex steroid hormones and risk of developing type 2 diabetes in women: A prospective study. Diabetologia 2007, 50, 2076-2084. [PubMed]
96. Kalyani, R.R.; Franco, M.; Dobs, A.S.; Ouyang, P.; Vaidya, D.; Bertoni, A.; Gapstur, S.M.; Golden, S.H. The association of endogenous sex hormones, adiposity, and insulin resistance with incident diabetes in postmenopausal women. J. Clin. Endocrinol. Metab. 2009, 94, 4127-4135. [CrossRef] [PubMed]
97. Daka, B.; Jansson, P.A.; Rosen, T.; Larsson, C.A.; Rastam, L.; Lindblad, U. Inverse association between serum insulin and sex hormone binding globulin in a population survey in Sweden. Endocr. Connect. 2012, 2, 18-22. [CrossRef] [PubMed]
98. Golden, S.H.; Dobs, A.S.; Vaidya, D.; Szklo, M.; Gapstur, S.; Kopp, P.; Liu, K.; Ouyang, P. Endogenous sex hormones and glucose tolerance status in postmenopausal women. J. Clin. Endocrinol. Metab. 2007, 92, 1289-1295. [CrossRef] [PubMed]
99. Esteva, F.J.; Hortobagyi, G.N. Prognostic molecular markers in early breast cancer. Breast Cancer Res. 2004, 6, 109-118. [CrossRef] [PubMed]
100. Berstein, L.M.; Tsrylina, E.V.; Poroshina, T.E.; Levina, V.V.; Vasilyev, D.A.; Kovalenko, I.G.; Semiglazov, V.F. Genotoxic factors associated with the development of receptor-negative breast cancer: Potential role of the phenomenon of switching of estrogen effects. Exp. Oncol. 2006, 28, 64-69. [PubMed]
101. Larsson, S.C.; Bergkvist, L.; Wolk, A. Glycemic load, glycemic index and breast cancer risk in a prospective cohort of Swedish women. Int. J. Cancer 2009, 125, 153-157. [CrossRef] [PubMed]
102. Rose, D.P.; Vona-Davis, L. The cellular and molecular mechanisms by which insulin influences breast cancer risk and progression. Endocr. Relat. Cancer 2012, 19, 225-241. [CrossRef] [PubMed]
103. Sun, X.; Casbas-Hernandez, P.; Bigelow, C.; Makowski, L.; Joseph Jerry, D.; Smith Schneider, S.; Troester, M.A. Normal breast tissue of obese women is enriched for macrophage markers and macrophage-associated gene expression. Breast Cancer Res. Treat. 2012, 131, 1003-1012. [CrossRef] [PubMed]
104. Morris, P.G.; Hudis, C.A.; Giri, D.; Morrow, M.; Falcone, D.J.; Zhou, X.K.; Du, B.; Brogi, E.; Crawford, C.B.; Kopelovich, L.; et al. Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev. Res. 2011, 4, 1021-1029. [CrossRef] [PubMed]
105. Zhao, Y.; Nichols, J.E.; Valdez, R.; Mendelson, C.R.; Simpson, E.R. Tumor necrosis factor-alpha stimulates aromatase gene expression in human adipose stromal cells through use of an activating protein-1 binding site upstream of promoter 1.4. Mol. Endocrinol. 1996, 11, 1350-1357.
106. Singh, A.; Purohit, A.; Ghilchik, M.W.; Reed, M.J. The regulation of aromatase activity in breast fibroblasts: The role of interleukin-6 and prostaglandin E2. Endocr. Relat. Cancer 1999, 6, 139-147. [CrossRef] [PubMed]
107. Subbaramaiah, K.; Morris, P.G.; Zhou, X.K.; Morrow, M.; Du, B.; Giri, D.; Kopelovich, L.; Hudis, C.A.; Dannenberg, A.J. Increased levels of COX-2 and prostaglandin E 2 contribute to elevated aromatase expression in inflamed breast tissue of obese women. Cancer Discov. 2012, 2, 356-365. [CrossRef] [PubMed]
108. Rogers, N.H.; Li, J.W.P.; Strissel, K.J.; Obin, M.S.; Greenberg, A.S. Reduced energy expenditure and increased inflammation are early events in the development of ovariectomy-induced obesity. Endocrinology 2009, 150, 2161-2168. [CrossRef] [PubMed]
109. Subbaramaiah, K.; Howe, L.R.; Bhardwaj, P.; Du, B.; Gravaghi, C.; Yantiss, R.K.; Zhou, X.K.; Blaho, V.A.; Hla, T.; Yang, P.; et al. Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prev. Res. 2011, 4, 329-346. [CrossRef] [PubMed]
110. Frasor, J.; Weaver, A.; Pradhan, M.; Dai, Y.; Miller, L.D.; Lin, C.Y.; Stanculescu, A. Positive cross-talk between estrogen receptor and NF-κB in breast cancer. Cancer Res. 2009, 69, 8918-8925. [CrossRef] [PubMed]
111. Jones, R.L.; Rojo, F.; A’Hern, R.; Villena, N.; Salter, J.; Corominas, J.M.; Servitja, S.; Smith, I.E.; Rovira, A.; Reis-Filho, J.S.; et al. Nuclear NF-κB/p65 expression and response to neoadjuvant chemotherapy in breast cancer. J. Clin. Pathol. 2011, 62, 130-135. [CrossRef] [PubMed]
112. Kim, E.; Choi, M.R.; Park, H.; Kim, M.; Hong, J.; Lee, J.Y.; Chun, H.; Lee, K.; Yoon Park, J. Dietary fat increases solid tumor growth and metastasis of 4T1 murine mammary carcinoma cells and mortality in obesity-resistant BALB/c mice. Breast Cancer Res. 2011, 13, R78. [CrossRef] [PubMed]
113. Berryhill, G.E.; Gloviczki, J.M.; Trott, J.F.; Aimo, L.; Kraft, J.; Cardiff, R.D.; Paul, C.T.; Petrie, W.K.; Lock, A.L.; Hovey, R.C. Diet-induced metabolic change induces estrogen-independent allometric mammary growth. Proc. Natl. Acad. Sci. 2012, 109, 16294-16299. [CrossRef] [PubMed]
114. Poirier, H.; Shapiro, J.S.; Kim, R.J.; Lazar, M.A. Nutritional supplementation with trans-10, cis-12-conjugated linoleic acid induces inflammation of white adipose tissue. Diabetes 2006, 55, 1634-1641. [CrossRef] [PubMed]
115. Cowen, S.; McLaughlin, S.; Hobbs, G.; Coad, J.; Martin, K.; Olfert, I.; Vona-Davis, L. High-fat, high-calorie diet enhances mammary carcinogenesis and local inflammation in MMTV-PyMT mouse model of breast cancer. Cancers 2015, 7, 1125-1142. [CrossRef] [PubMed]
116. Francés, D.E.; Motiño, O.; Agrá, N.; González-Rodríguez, A.; Fernández-Álvarez, A.; Cucarella, C.; Mayoral, R.; Castro-Sánchez, L.; García-Casarrubios, E.; Boscá, L.; et al. Hepatic cyclooxygenase-2 expression protects against diet-induced steatosis, obesity and insulin resistance. Diabetes 2014, 64, 1522-1531.
117. Kosacka, J.; Kern, M.; Klöting, N.; Paeschke, S.; Rudich, A.; Haim, Y.; Gericke, M.; Serke, H.; Stumvoll, M.; Bechmann, I.; et al. Autophagy in adipose tissue of patients with obesity and type 2 diabetes. Mol. Cell. Endocrinol. 2015, 409, 21-32. [CrossRef] [PubMed]
118. Eichbaum, C.; Meyer, A.S.; Wang, N.; Bischofs, E.; Steinborn, A.; Bruckner, T.; Brodt, P.; Sohn, C.; Eichbaum, M.H.R. Breast cancer cell-derived cytokines, macrophages and cell adhesion: Implications for metastasis. Anticancer Res. 2011, 31, 3219-3227. [PubMed]
119. Hagemann, T.; Wilson, J.; Kulbe, H.; Li, N.F.; Leinster, D.A.; Charles, K.; Klemm, F.; Pukrop, T.; Binder, C.; Balkwill, F.R. Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J. Immunol. 2005, 175, 1197-1205. [CrossRef] [PubMed]
120. Kim, S.; Jae, H.C.; Jong, B.K.; Seok, J.N.; Yang, J.H.; Kim, J.H.; Jeong, E.L. Berberine suppresses TNF-α-induced MMP-9 and cell invasion through inhibition of AP-1 activity in MDA-MB-231 human breast cancer cells. Molecules 2008, 13, 2975-2985. [CrossRef] [PubMed]
121. Walter, M.; Liang, S.; Ghosh, S.; Hornsby, P.J.; Li, R. Interleukin 6 secreted from adipose stromal cells promotes migration and invasion of breast cancer cells. Oncogene 2009, 28, 2745-2755. [CrossRef] [PubMed]
122. Goldberg, J.E.; Schwertfeger, K.L. Proinflammatory cytokines in breast cancer: Mechanisms of action and potential targets for therapeutics. Curr. Drug Targets 2010, 11, 1133-1146. [CrossRef] [PubMed]
123. Herrera, A.C.; Panis, C.; Victorino, V.J.; Campos, F.C.; Coloado-Simao, A.N.; Cecchini, A.L.; Cecchini, R. Molecular subtype is determinant on inflammatory status and immunological profile from invasive breast cancer patients. Cancer Immunol. Immunother. 2012, 61, 2193-2201. [CrossRef] [PubMed]
124. Turkoz, F.P.; Solak, M.; Petekkaya, I.; Keskin, O.; Kertmen, N.; Sarici, F.; Arik, Z.; Babacan, T.; Ozisik, Y.; Altundag, K. The prognostic impact of obesity on molecular subtypes of breast cancer in premenopausal women. J. BUON 2013, 18, 335-341. [PubMed]
125. Sethi, S.; Sarkar, F.H.; Ahmed, Q.; Bandyopadhyay, S.; Nahleh, Z.A.; Semaan, A.; Sakr, W.; Munkarah, A.; Ali-Fehmi, R. Molecular markers of epithelial-to-mesenchymal transition are associated with tumor aggressiveness in breast carcinoma. Transl. Oncol. 2011, 4, 222-226. [CrossRef] [PubMed]
126. Rody, A.; Karn, T.; Liedtke, C.; Pusztai, L.; Ruckhaeberle, E.; Hanker, L.; Gaetje, R.; Solbach, C.; Ahr, A.; Metzler, D.; et al. A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res. 2011, 13, R97. [PubMed]
127. Hartman, Z.C.; Poage, G.M.; Den Hollander, P.; Tsimelzon, A.; Hill, J.; Panupinthu, N.; Zhang, Y.; Mazumdar, A.; Hilsenbeck, S.G.; Mills, G.B.; et al. Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. Cancer Res. 2013, 73, 3470-3480. [CrossRef] [PubMed]
128. Gillespie, E.F.; Sobero, M.E.; Hanauer, D.A.; Sabel, M.S.; Herrmann, E.J.; Weiser, L.J.; Jagielski, C.H.; Griggs, J.J. Obesity and angiolymphatic invasion in primary breast cancer. Ann. Surg. Oncol. 2010, 17, 752-759. [CrossRef] [PubMed]
129. Maiti, B.; Kundranda, M.N.; Spiro, T.P.; Daw, H.A. The association of metabolic syndrome with triple-negative breast cancer. Breast Cancer Res. Treat. 2010, 121, 479-483. [CrossRef] [PubMed]
130. Corvera, S.; Gealekman, O. Adipose tissue angiogenesis: Impact on obesity and type-2 diabetes. Biochem. Biophys. Acta 2014, 1842, 463-472. [CrossRef] [PubMed]
131. Uzzan, B.; Nicolas, P.; Cucherat, M.; Perret, G.Y. Microvessel density as a prognostic factor in women with breast cancer: A systematic review of the literature and meta-analysis. Cancer Res. 2004, 64, 2941-2955. [CrossRef] [PubMed]
132. Cancello, R.; Henegar, C.; Viguerie, N.; Taleb, S.; Poitou, C.; Rouault, C.; Coupaye, M.; Pelloux, V.; Hugol, D.; Bouillot, J.L.; et al. Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes 2005, 54, 2277-2286. [CrossRef] [PubMed]
133. Hirsch, H.A.; Iliopoulos, D.; Struhl, K. Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proc. Natl. Acad. Sci. USA 2013, 110, 972-977. [CrossRef] [PubMed]